Wasting drug under consideration
A drug to treat HIV-related facial wasting will be considered for government subsidies by the independent Pharmaceutical Benefits Advisory Committee next month.
Several HIV organisations have begun lobbying to get Sculptra on the Pharmaceutical Benefits Scheme (PBS) list during the two-week period of public consultation.
Facial Lipoatrophy is an adverse effect of HIV treatment and can have a physical and psychological impact on people who experience it. Many people have found treatment with Sculptra restores facial fullness, and hence improves their quality of life, Positive Life wrote to its members this week.
Submissions can be made until 8 October via the PBAC website.
